We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial) (Power-UP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00826774
Recruitment Status : Completed
First Posted : January 22, 2009
Last Update Posted : May 15, 2012
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
The purpose of the study is to compare three methods of achieving weight loss in primary care medical practice. The study will be conducted in six primary care practices. Weight management will be provided to a total of 390 obese patients (who have 2 or more components of the metabolic syndrome) by their own primary care providers, in conjunction with the practices' auxiliary health professionals, including medical assistants.

Condition or disease Intervention/treatment Phase
Obesity Hypercholesterolemia Metabolic Syndrome Hypertension Diabetes Behavioral: Usual Care Behavioral: Brief Lifestyle Counseling Behavioral: Enhanced Brief Lifestyle Counseling Phase 3

Detailed Description:

Obesity, defined by a body mass index (BMI) ≥ 30 kg/m2, affects more than 31% of American adults. Additionally, nearly one-quarter of U.S. adults meet criteria for the metabolic syndrome, a clustering of clinical signs (i.e., elevated waist circumference, blood pressure, glucose or triglycerides, decreased HDL cholesterol) that is associated with increased risk of cardiovascular death. Behavior modification programs and pharmacologic interventions for obesity typically result in an 8% to 10% loss of initial body weight. Losses of this magnitude are associated with clinically significant improvements in metabolic parameters among obese persons. The availability of traditional behavioral weight control programs, however, is limited as many of these programs are based in academic medical centers. Furthermore, pharmacotherapy is seldom covered by third-party payers. Thus, there are concerns about the accessibility of these interventions to the many obese individuals who could benefit from weight loss.

The purpose of the study is to improve the management of obesity in primary care practice, where obesity is commonly encountered but infrequently addressed. Three hundred and ninety persons at 6 primary care practices within the University of Pennsylvania Health System will be randomized to one of three 2-year interventions: Usual Care, Brief Lifestyle Counseling, or Enhanced Brief Lifestyle Counseling. After training in obesity management and intervention strategies, each site will enroll approximately 65 individuals with a BMI of 30-50 kg/m2 plus two or more components of the metabolic syndrome. Participants in the Usual Care condition (N=130) will receive educational materials plus quarterly visits with a primary care provider (PCP). Those in the Brief Lifestyle Counseling condition (N=130) will receive the same PCP visits, plus 26 brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone. Participants in the Enhanced Brief Lifestyle Counseling condition (N=130) will additionally receive the same treatment as those in the Brief Lifestyle Counseling group, plus the choice of adjunctive meal replacements or pharmacotherapy.

Two-year changes in weight will be compared across groups. Participants who receive the Brief Lifestyle Counseling and the Enhanced Brief Lifestyle Counseling interventions are predicted to achieve greater weight loss than those who receive Usual Care. A secondary hypothesis is that participants in Enhanced Brief Lifestyle Counseling condition will lose significantly more weight at month 24 than participants in the Brief Lifestyle Counseling group. Secondary analysis will also compare changes in the metabolic syndrome (and its individual components), mood, quality of life, dietary intake, eating behavior, appetite, physical activity and sexual function, as well as cost-effectiveness, among the three conditions. Intervention protocols and study results will be disseminated to other health care providers and payers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 390 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Practice-based Opportunities for Weight Reduction Trial at University of Pennsylvania
Study Start Date : January 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Active Comparator: Ususal Care Behavioral: Usual Care
Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.

Experimental: Breif Lifestyle Counseling Behavioral: Brief Lifestyle Counseling
These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.

Experimental: Enhanced Brief Lifestyle Counseling Behavioral: Enhanced Brief Lifestyle Counseling
These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss

Primary Outcome Measures :
  1. Weight [ Time Frame: Measured at Month 24 ]

Secondary Outcome Measures :
  1. Prevalence of the metabolic syndrome [ Time Frame: at 24 months ]
  2. Blood Pressure [ Time Frame: at 24 months ]
  3. Lipid levels [ Time Frame: at 24 months ]
  4. Sexual function [ Time Frame: at 24 months ]
  5. Mood [ Time Frame: at 24 months ]
  6. Homeostasis model assessment of insulin resistance (HOMA-IR) [ Time Frame: at 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age ≥ 21 years

    • BMI 30-50 kg/m2 and weight ≤ 400 lbs.
    • At least 2 of 5 criteria for metabolic syndrome

      • Elevated waist circumference (> 102 cm for men, > 88 cm for women)
      • Elevated blood pressure (≥ 130/85 mmHg)
      • Impaired fasting glucose (≥ 100 mg/dl)
      • Elevated triglycerides (≥ 150 mg/dl)
      • Low HDL cholesterol (< 40 for men, < 50 mg/dl for women)
    • Willing to change diet, physical activity and weight
    • Willing to accept randomization to each group
    • Able to give informed consent
    • Patient of participating PCP

Persons with the following conditions are eligible with PCP approval:

  • Diabetes mellitus
  • Prior CVD event > 6 months before randomization
  • Stable CVD or peripheral vascular disease

Exclusion Criteria:

  • Serious medical condition likely to hinder accurate measurement of weight, or for which weight loss is contraindicated, or which would cause weight loss (e.g., end-stage renal disease on dialysis, cancer diagnosis or treatment within 2 yrs)
  • Prior or planned bariatric surgery
  • Chronic use (at least past 6 months) of medications likely to cause weight gain or prevent weight loss (e.g. corticosteroids, lithium, olanzapine, risperidone, clozapine)
  • Unintentional weight loss within 6 months of enrollment (≥ 5% of body weight)
  • Intentional weight loss within 6 months of enrollment (≥ 5% of body weight)
  • Pregnant or nursing within past 6 months
  • Plans to relocate from the area within 2 years
  • Another member of household is a study participant or staff in the trial
  • Consumes > 14 alcoholic drinks per week
  • Current use of illicit substances
  • Psychiatric hospitalization in last year
  • Psychiatric condition likely to impair adherence to treatment (e.g., schizophrenia)
  • Blood pressure ≥ 160/100 mmHg; patient may be re-screened in 1 month
  • Principal Investigator or PCP discretion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826774

Sponsors and Collaborators
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Thomas A Wadden, PhD University of Pennsylvania
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00826774    
Other Study ID Numbers: 805684
U01HL087072 ( U.S. NIH Grant/Contract )
First Posted: January 22, 2009    Key Record Dates
Last Update Posted: May 15, 2012
Last Verified: May 2012
Keywords provided by University of Pennsylvania:
Body Weight
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Nutrition Disorders
Body Weight
Vascular Diseases
Cardiovascular Diseases
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders